The California-based entities plan to offer new Medicare Advantage (MA) products in select counties by this fall.

Pediatric patients with prior SARS-CoV-2 infection had a higher risk of adverse postacute kidney outcomes, such as new-onset ...

ECHELON-3 (NCT04404283) principal investigator Craig A. Portell, MD, speaks to the significance of this triplet approval from ...

Several court cases have been filed against the Trump administration over disruptions touching health care, including funding ...

Despite significant advancements in spinal muscular atrophy (SMA) management, unmet needs persist, especially for patients ...

Experts discuss how to evaluate and communicate the return on investment for continuous glucose monitoring (CGM) coverage to ...

New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of ...

Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month for proteinuria reduction.

Study participants treated with elinzanetant experienced significantly reduced hot flash frequency vs paroxetine, ...

As Medicare Advantage (MA) enrollment grows, Johnie Rose, MD, PhD, Case Western Reserve University School of Medicine, ...

A group of experts discusses the use of continuous glucose monitoring (CGM) technology in diabetes and its transformative ...

Experts discuss the disparities observed in continuous glucose monitoring (CGM) access and utilization with Healthcare Effectiveness Data and Information Set (HEDIS) now stratifying 22 measures by ...